Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:42:05.506Z.
Calculation as of: 2026-10-06T19:42:05.506Z.
Quote observation: 2026-10-06T19:40:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$27.65M
Price/FCF Ratio
N/A
TTM Avg
87.13
3Y Avg
87.13
5Y Avg
45.44
Market Cap
$24.51M
Price/FCF Ratio
N/A
TTM Avg
242.89
3Y Avg
242.89
5Y Avg
242.89
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $26.49M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.65M | N/A | 87.13 | 87.13 | 45.44 |
| aTyr Pharma, Inc. (ATYR)vs › | $27.93M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $24.60M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.51M | N/A | 242.89 | 242.89 | 242.89 |
| OneMedNet Corporation (ONMD)vs › | $28.93M | N/A | 2.82 | 2.82 | 2.82 |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $28.94M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $23.96M | N/A | 118.09 | 118.84 | 145.02 |
| BeyondSpring Inc. (BYSI)vs › | $29.20M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
